These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 2043500)

  • 1. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
    Philip T; Chauvin F; Bron D; Guglielmi C; Hagenbeek A; Coiffier B; Gisselbrecht C; Kluin Nelemans JC; Somers R; Misset JC
    Ann Oncol; 1991 Jan; 2 Suppl 1():57-64. PubMed ID: 2043500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.
    Philip T; Chauvin F; Armitage J; Bron D; Hagenbeek A; Biron P; Spitzer G; Velasquez W; Weisenburger DD; Fernandez-Ranada J
    Blood; 1991 Apr; 77(7):1587-92. PubMed ID: 2009374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin, and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized italian multicenter study.
    Martelli M; Vignetti M; Zinzani PL; Gherlinzoni F; Meloni G; Fiacchini M; De Sanctis V; Papa G; Martelli MF; Calabresi F; Tura S; Mandelli F
    J Clin Oncol; 1996 Feb; 14(2):534-42. PubMed ID: 8636768
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group.
    Blay J; Gomez F; Sebban C; Bachelot T; Biron P; Guglielmi C; Hagenbeek A; Somers R; Chauvin F; Philip T
    Blood; 1998 Nov; 92(10):3562-8. PubMed ID: 9808548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
    Santini G; Salvagno L; Leoni P; Chisesi T; De Souza C; Sertoli MR; Rubagotti A; Congiu AM; Centurioni R; Olivieri A; Tedeschi L; Vespignani M; Nati S; Soracco M; Porcellini A; Contu A; Guarnaccia C; Pescosta N; Majolino I; Spriano M; Vimercati R; Rossi E; Zambaldi G; Mangoni L; Rizzoli V
    J Clin Oncol; 1998 Aug; 16(8):2796-802. PubMed ID: 9704732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of cytoreductive therapy prior to high dose treatment with autologous bone marrow transplantation in relapsed and refractory Hodgkin's disease.
    Brandwein JM; Callum J; Sutcliffe SB; Scott JG; Keating A
    Bone Marrow Transplant; 1990 Feb; 5(2):99-103. PubMed ID: 2310878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
    J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose sequential chemotherapy followed by autologous stem cell transplantation in relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a multicenter phase II study.
    Josting A; Sieniawski M; Glossmann JP; Staak O; Nogova L; Peters N; Mapara M; Dörken B; Ko Y; Metzner B; Kisro J; Diehl V; Engert A
    Ann Oncol; 2005 Aug; 16(8):1359-65. PubMed ID: 15939712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous transplantation for aggressive non-Hodgkin's lymphoma: results of a randomized trial evaluating graft source and minimal residual disease.
    Vose JM; Sharp G; Chan WC; Nichols C; Loh K; Inwards D; Rifkin R; Bierman PJ; Lynch JC; Weisenburger DD; Kessinger A; Armitage JO
    J Clin Oncol; 2002 May; 20(9):2344-52. PubMed ID: 11981006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carmustine, Ara C, cyclophosphamide and etoposide with autologous bone marrow transplantation in relapsed or refractory lymphoma: a dose-finding study.
    Snyder MJ; Johnson DB; Daly MB; Giguere JK; Harman GH; Harden EA; Johnson RA; Leff RS; Mercier RJ; Messerschmidt GL
    Bone Marrow Transplant; 1994 Oct; 14(4):595-600. PubMed ID: 7858534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma.
    Philip T; Guglielmi C; Hagenbeek A; Somers R; Van der Lelie H; Bron D; Sonneveld P; Gisselbrecht C; Cahn JY; Harousseau JL
    N Engl J Med; 1995 Dec; 333(23):1540-5. PubMed ID: 7477169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP.
    Verdonck LF; Dekker AW; de Gast GC; van Kempen ML; Lokhorst HM; Nieuwenhuis HK
    J Clin Oncol; 1992 Dec; 10(12):1949-54. PubMed ID: 1453209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data.
    Horning SJ; Chao NJ; Negrin RS; Hoppe RT; Kwak LW; Long GD; Stallbaum B; O'Connor P; Blume KG
    Ann Oncol; 1991 Jan; 2 Suppl 1():47-50. PubMed ID: 2043498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
    Weaver CH; Schwartzberg L; Rhinehart S; West J; Zhen B; West WH; Buckner CD
    Bone Marrow Transplant; 1998 Feb; 21(4):383-9. PubMed ID: 9509973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Jagannath S; Armitage JO; Dicke KA; Tucker SL; Velasquez WS; Smith K; Vaughan WP; Kessinger A; Horwitz LJ; Hagemeister FB
    J Clin Oncol; 1989 Feb; 7(2):179-85. PubMed ID: 2644397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of recent salvage chemotherapy regimens for lymphoma and Hodgkin's disease.
    Cabanillas F; Velasquez WS; McLaughlin P; Jagannath S; Hagemeister FB; Redman JR; Swan F; Rodriguez MA
    Semin Hematol; 1988 Apr; 25(2 Suppl 2):47-50. PubMed ID: 3041599
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.